Shares of Pfizer Inc. PFE slipped 2.26% to $25.55 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,776.65 and ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

From 2024 to 2026, analysts expect its revenue to rise at a two-year CAGR of 28% to $168 million as its adjusted EBITDA grows ...

We recently published a list of 14 Best Affordable Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Pfizer closed at $25.60, slipping 0.43% in the latest session, outperforming broader market losses. While the S&P 500 dropped ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

Low bond yields and interest rates are often credited with supporting higher prices in the stock market. That's because lower bond yields can make the potentially higher yields offered by stocks ...

These Chinese companies are also in a position to assign a lower price to these medicines compared to ... If you are looking ...

Analysts believe that while Pfizer faced a steep decline after its COVID-19 boom, the stock’s current valuation presents a compelling opportunity. The company is actively advancing its oncology ...